Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm
- 245 Downloads
A double-blind study was performed on 212 consecutive patients (58 men, 154 women) with essential blepharospasm, who received one injection of Botox and one injection of Dysport in two separate treatment sessions (at the first session the patients randomly received one of the drugs, at the second the other drug was given. The patients' mean age was 66.4 years ± 8.14 (range 39–86 years). The average dose of Botox per treatment was 45.4 IU ± 13.3 (range 25–85 IU) and of Dysport 182.1 IU ± 55.1 (range 100–340 IU). We used an empirical ratio Botox:Dysport of 1:4 (IU) in order to ensure equal doses. All patients had received botulinum toxin injections prior to the present study (mean 15.3 injections ± 9.4; range 1–43 injections). The effect of Botox lasted 7.98 weeks ± 3.8 (range 0–16 weeks), while the effect of Dysport lasted 8.03 weeks ± 4.6 (range 0–22 weeks). Side effects (ptosis, tearing, blurred vision, double vision, hematoma, foreign body sensation) were observed with Botox in 36 of 212 (17.0%) of the treatment sessions and with Dysport in 51 of 212 sessions (24.1%). Ptosis was observed with Botox in 3 cases (1.4%) and with Dysport in 14 cases (6.6%). There was no statistically significant difference in the duration of the treatment effect between the two preparations (P=0.42). The total number of side effects was lower with Botox than with Dysport; the significance of the difference was moderate (P<0.05). However, the rate of occurrence of ptosis was significantly lower with Botox (P<0.01). The bioequivalence, which varies between 1:3 and 1:6 (Botox:Dysport) in the literature, was found to be 1:4 in this study.
KeywordsForeign Body Botulinum Toxin Treatment Session Average Dose Body Sensation
Unable to display preview. Download preview PDF.
- 1.Borodic GE, Ferrante R, Pearce LB, Smith K (1994) Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections. Mov Disord 9:31–39Google Scholar
- 2.Durif F (1995) Clinical bioequivalence of the current commercial preparations of botulinum toxin. Eur J Neurol 2:17–18Google Scholar
- 3.Marion MH, Sheehy M, Sangla S, Soulayrol S (1995) Dose standardisation of botulinum toxin. (letter) J Neurol Neurosurg Psychiatr 59:102–103Google Scholar
- 4.Pickett AM, Hambleton P (1994) Dose standardisation of botulinum toxin. Lancet 344:474–475Google Scholar
- 5.Ruban JM, Pellissier de Féligonde O, Benillouche P (1993) Analyse de l'efficacité de la toxine botulique A dans le traitement du blépharospasme et de l'hémispasme facial. Ophtalmologie (Paris) 7:481–482Google Scholar
- 6.Sampaio C, Ferreira JJ, Simões F, Rosas MJ, Magalhaes M, Martins R, Bastos-Lima A, Castro-Caldas A (1995) Dysbot: a single blind, randomized clinical trial to compare two different formulations of botulinum toxin type A. Mov Disord 10:387Google Scholar